Respiratory diseases

My approach to infectious diseases has always been multi-disciplinary. There is a constant arms race between both host and pathogen. Infection changes the host response and the host response exerts changes on the pathogen. Approaching these problems from a single host or pathogen centric view limits the chance for complete understanding. Most of my published works have been in the interface between both the host and the pathogen. Joining Bio5 will allow me to join other scientist interested in multi-disciplinary answers to complex questions.

Dr. Fernando D. Martinez is a Regents’ Professor and Director of the Asthma & Airway Disease Research Center at the University of Arizona in Tucson. Dr. Martinez is a world-renowned expert, and one of the most highly regarded researchers, in the field of childhood asthma. His primary research interests are the natural history, genetics, and treatment of childhood asthma. His groundbreaking research has had an impact on his field in numerous ways, most prominent among them the development of the concept of the early origins of asthma and COPD. This concept is now widely accepted as the potential basis for the design of new strategies for the prevention of these devastating illnesses affecting millions of children and adults worldwide. In addition, Dr. Martinez has made important contributions to our understanding of the role of gene-environment interactions in the development of asthma and allergies. He has also been the principal investigator of one of the Clinical Centers that are part of the NHLBI Asthma Treatment Networks, which have contributed fundamental new evidence on which to base national guidelines for the treatment of the disease. Dr. Martinez currently serves on national scientific boards including the NHLBI National Advisory Council and the National Scientific Council on the Developing Child. He was a member of the National Asthma Education and Prevention Program that was responsible for the development of the Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma in 1997 and its first revision in 2001. He also has been a member of the FDA Pulmonary-Allergy Drugs Advisory Committee and the Board of Extramural Advisors of the National Heart, Lung, and Blood Institute (NHLBI). Dr. Martinez’s research and vision are well detailed in more than 250 original research papers and editorials, many in collaboration with investigators from all over the world. He is frequently invited to give keynote presentations at national and international meetings.

Dr. Ledford’s current work in the area of pulmonary surfactant immunobiology combines her knowledge of mouse genetics, pulmonary disease models and immune function regulation and focuses on understanding the role of Surfactant Protein-A (SP-A) and how it regulates signaling pathways within various immune cell populations. Specifically, she is interested in how SP-A regulates degranulation, either directly or indirectly, of two important cell types in asthma: mast cells and eosinophils. More recently, Dr. Ledford’s research has focused on understanding how genetic variation within human SP-A2 alters functionality of the protein in relation to eosinophil activities and how this translates to characteristics observed in human asthma.

Stefano Guerra, MD, PhD, is a professor of Medicine, the Director of the Population Science Unit at the Asthma and Airway Disease Research Center, and a leading expert in the natural history and biomarkers of obstructive lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). As principal investigator, he is engaged in the leadership and coordination of multiple studies that use bio-specimens and phenotypic information from independent epidemiological cohorts to characterize the natural history, profile the risk factors, and identify novel biomarkers of lung diseases.

I am a senior research scientist and oversees medicinal chemistry research at BIO5 Institute's drug discovery initiative. I oversee group of medicinal chemistry involved in the development of small molecule therapeutics for idiopathic pulmonary fibrosis (IPF), neuropathic pain, acute lung injury and cancer. I am co-founder of Reglagene and Regulonix - two biotech companies with startup technology from the University of Arizona. I have 15 years' experience in medicinal chemistry with expertise in translational drug development. I am also a co-inventor of small molecules targeting hTERT and MYC for the treatment of glioblastoma, melanoma, lymphomas and prostate cancer. Our work in the area of neuropathic pain has led to successful funding from Tech Launch Arizona and will result in STTR funding from NIH.